Literature DB >> 24485753

EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness.

T Rüther1, J Bobes2, M De Hert3, T H Svensson4, K Mann5, A Batra6, P Gorwood7, H J Möller8.   

Abstract

Tobacco dependence is the most common substance use disorder in adults with mental illness. The prevalence rates for tobacco dependence are two to four times higher in these patients than in the general population. Smoking has a strong, negative influence on the life expectancy and quality of life of mental health patients, and remains the leading preventable cause of death in this group. Despite these statistics, in some countries smokers with mental illness are disadvantaged in receiving intervention and support for their tobacco dependence, which is often overlooked or even tolerated. This statement from the European Psychiatric Association (EPA) systematically reviews the current evidence on tobacco dependence and withdrawal in patients with mental illness and their treatment. It provides seven recommendations for the core components of diagnostics and treatment in this patient group. These recommendations concern: (1) the recording process, (2) the timing of the intervention, (3) counselling specificities, (4) proposed treatments, (5) frequency of contact after stopping, (6) follow-up visits and (7) relapse prevention. They aim to help clinicians improve the care, health and well-being of patients suffering from mental illness.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Affective disorders; Mental disorders; Schizophrenia; Smoking; Tobacco dependence; Tobacco use cessation

Mesh:

Year:  2014        PMID: 24485753     DOI: 10.1016/j.eurpsy.2013.11.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  30 in total

1.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

2.  Big data and meaning: methodological innovations.

Authors:  K S Bhui
Journal:  Epidemiol Psychiatr Sci       Date:  2015-01-30       Impact factor: 6.892

Review 3.  A perfect match: noninvasive brain stimulation and psychotherapy.

Authors:  Malek Bajbouj; Frank Padberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-25       Impact factor: 5.270

Review 4.  Clozapine in primary care.

Authors:  Karl Winckel; Dan Siskind
Journal:  Aust Prescr       Date:  2017-12-04

Review 5.  Alcohol Dependence and Harmful Use of Alcohol.

Authors:  Anil Batra; Christian A Müller; Karl Mann; Andreas Heinz
Journal:  Dtsch Arztebl Int       Date:  2016-04-29       Impact factor: 5.594

Review 6.  Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.

Authors:  Corinne Cather; Gladys N Pachas; Kristina M Cieslak; A Eden Evins
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 5.749

Review 7.  Cardiovascular disease in patients with severe mental illness.

Authors:  René Ernst Nielsen; Jytte Banner; Svend Eggert Jensen
Journal:  Nat Rev Cardiol       Date:  2020-10-30       Impact factor: 32.419

Review 8.  Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.

Authors:  Winifred Ekezie; Rachael L Murray; Sanjay Agrawal; Ilze Bogdanovica; John Britton; Jo Leonardi-Bee
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

9.  [Psychiatric comorbidities with tobacco-related disorders].

Authors:  S Mühlig; S Andreas; A Batra; K U Petersen; E Hoch; T Rüther
Journal:  Nervenarzt       Date:  2016-01       Impact factor: 1.214

10.  Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial.

Authors:  Arthur L Brody; Todd Zorick; Robert Hubert; Gerhard S Hellemann; Shabnam Balali; Sarah S Kawasaki; Lizette Y Garcia; Ryutaro Enoki; Paul Abraham; Paulina Young; Charles McCreary
Journal:  Nicotine Tob Res       Date:  2016-08-03       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.